Clinical Impact of Supraclavicular Lymph Node Involvement of Stage IIIC Non-Small Cell Lung Cancer Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sunmin | - |
dc.contributor.author | Yoon, Won Sup | - |
dc.contributor.author | Jang, Mi Hee | - |
dc.contributor.author | Rim, Chai Hong | - |
dc.date.accessioned | 2021-11-23T14:40:20Z | - |
dc.date.available | 2021-11-23T14:40:20Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1010-660X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128483 | - |
dc.description.abstract | Background and Objective: Investigations on the clinical impact of supraclavicular lymph node (SCN) involvement in stage IIIC non-small cell lung cancer (NSCLC) remain scarce. We evaluated the oncological outcomes of definitive radiochemotherapy and the clinical significance of SCN involvement. Materials and Methods: Between November 2009 and June 2019, a total of 40 patients with N3-positivity and NSCLC were evaluated. Most patients received concomitant chemotherapy, but six patients who received radiotherapy (RT) alone were also included. Twenty-one patients (52.5%) received 3D-conformal RT (3DCRT), and the remainder received intensity-modulated RT (IMRT). Results: The median follow-up duration was 10.7 months (range: 1.7-120.6 months). Median overall survival (OS) and cause-specific survival (CSS) times were 10.8 months and 16.3 months, respectively. Among the 40 patients, 17 (42.5%) had SCN involvement. SCN involvement negatively affected progression-free survival (hazard ratio (HR): 2.08, 95% confidence interval (CI): 1.04-4.17, p = 0.039) and local control (HR: 3.05, 95% CI: 1.09-8.50, p = 0.034). However, IMRT use was correlated with higher local control (HR: 0.28, 95% CI: 0.09-0.86, p = 0.027). Grade >= 3 esophagitis and pneumonitis accounted for 7.5% and 15.0% of all cases, respectively. A higher RT dose (mean dose: 66.6 vs. 61.7 Gy) was significantly correlated with grade >= 3 pneumonitis (p = 0.001). RT modality was a significant factor (p = 0.042, five of six cases occurred in the IMRT group). Conclusions: SCN involvement could negatively affect oncologic outcomes of stage IIIC NSCLC patients. High-dose irradiation with IMRT could increase local control but may cause lung toxicities. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Clinical Impact of Supraclavicular Lymph Node Involvement of Stage IIIC Non-Small Cell Lung Cancer Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Won Sup | - |
dc.contributor.affiliatedAuthor | Rim, Chai Hong | - |
dc.identifier.doi | 10.3390/medicina57030301 | - |
dc.identifier.scopusid | 2-s2.0-85103862314 | - |
dc.identifier.wosid | 000633845500001 | - |
dc.identifier.bibliographicCitation | MEDICINA-LITHUANIA, v.57, no.3 | - |
dc.relation.isPartOf | MEDICINA-LITHUANIA | - |
dc.citation.title | MEDICINA-LITHUANIA | - |
dc.citation.volume | 57 | - |
dc.citation.number | 3 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordAuthor | non-small cell lung carcinoma | - |
dc.subject.keywordAuthor | radiochemotherapy | - |
dc.subject.keywordAuthor | intensity-modulated radiotherapy | - |
dc.subject.keywordAuthor | supraclavicular lymph node | - |
dc.subject.keywordAuthor | NSCLC IIIC | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.